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Abstract
The immunogenicity and the efficacy of a beta-propiolactone-inactivated caprine herpesvirus 1 (CpHV-1) vaccine
adjuvanted with MF59
TM were tested in goats. Following two subcutaneous immunizations, goats developed high titers of
CpHV-1-specific serum and vaginal IgG and high serum virus neutralization (VN) titers. Peripheral blood mononuclear cells
(PBMC) stimulated in vitro with inactivated CpHV-1 produced high levels of soluble IFN-gamma and exhibited high
frequencies of IFN-gamma producing cells while soluble IL-4 was undetectable. On the other hand, control goats receiving
the inactivated CpHV-1 vaccine without adjuvant produced only low serum antibody responses. A vaginal challenge with
virulent CpHV-1 was performed in all vaccinated goats and in naı ¨ve goats to assess the efficacy of the two vaccines. Vaginal
disease was not detected in goats vaccinated with inactivated CpHV-1 plus MF59
TM and these animals had undetectable
levels of infectious challenge virus in their vaginal washes. Goats vaccinated with inactivated CpHV-1 in the absence of
adjuvant exhibited a less severe disease when compared to naı ¨ve goats but shed titers of challenge virus that were similar
to those of naı ¨ve goats. Detection and quantitation of latent CpHV-1 DNA in sacral ganglia in challenged goats revealed that
the inactivated CpHV-1 plus MF59
TM vaccine was able to significantly reduce the latent viral load when compared either to
the naı ¨ve goats or to the goats vaccinated with inactivated CpHV-1 in the absence of adjuvant. Thus, a vaccine composed of
inactivated CpHV-1 plus MF59
TM as adjuvant was strongly immunogenic and induced effective immunity against vaginal
CpHV-1 infection in goats.
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Introduction
Caprine herpesvirus 1 (CpHV-1) is an Alphaherpesvirus [1]
responsible for lethal systemic infections in 1- to 2-week-old kids
[2,3] and for mild to subclinical infections in adult goats [4,5].
Clinical manifestations in adult goats involve the respiratory or the
reproductive tract [6] depending on the site of virus entry although
CpHV-1 infects preferentially the genital mucosa. Following
primary genital infection, the virus replicates in the mucosal
epithelium and spreads to sacral ganglia to establish latency [7].
Genital CpHV-1 infections are characterized by painful erythem-
atous-oedematous lesions evolving into vesicles and ulcers healing
in two weeks [8]; balanoposthitis, vaginitis, infertility or abortion
are often observed during primary or recurrent infections.
Although the CpHV-1 infection is distributed worldwide and
major economical losses occur in Mediterranean countries, no
vaccines are commercially available. An ideal vaccine against
CpHV-1 should prevent primary infection and replication in the
vaginal mucosa and should interfere with the establishment of
latency; in fact, reactivation of latent virus and mucosal shedding
are responsible for CpHV-1 transmission to other animals in the
same flock and to newborns. Interestingly, CpHV-1 shares several
biological features with human HSV-2, such as, the tropism for the
vaginal epithelium, the type of genital lesions and the establish-
ment of latency in sacral ganglia [7,9,10].
Experimental studies in goats have shown that parenteral
immunization with inactivated CpHV-1 plus Montanide ISA
TM
740 or vaginal immunization with inactivated CpHV-1 plus
LTK63, provide partial protection against a vaginal challenge with
virulent CpHV-1 [11,12]. In addition, intranasal vaccination with
a live attenuated gE negative Bovine herpesvirus 1 (BoHV-1)
vaccine was shown to confer partial cross-reactive protection to
goats challenged vaginally with CpHV-1 [13]. Collectively, the
above studies have suggested that either virus neutralization (VN)
activity in serum or CpHV-1-specific vaginal IgA contribute to
protection although the precise role played by antibody responses
to protection against vaginal CpHV-1 infection needs to be
specifically addressed. In addition, the role played by cell-mediated
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tion remains unknown.
The present study was undertaken to determine if the use of a
potent adjuvant could augment the immunogenicity and the
protective efficacy of an inactivated CpHV-1 vaccine. To this end,
goats were subcutaneously immunized with a beta-propiolactone-
inactivated CpHV-1 vaccine and MF59
TM as adjuvant. The oil-
in-water emulsion MF59
TM was employed since it is licensed for
human use with an influenza vaccine since 1997 [14], it has a large
safety database [15,16] and it is known to induce both antibody
and cell-mediated immune responses in various preclinical models
and humans [14,17] although it has never been tested for efficacy
in ruminants.
The results presented herein provide the first evidence that the
addition of the MF59
TM adjuvant greatly enhances the immuno-
genicity and protection afforded by an inactivated CpHV-1
vaccine.
Materials and Methods
Ethics Statement
The experiments were approved by the Italian Ministry of
Health (Prot. n. 2174/07) and were carried out at the University of
Bari according to the National Guide for Care and Use of
Experimental Animals.
Animals
Twenty-eight female goats (18 months-2 years) of mixed breed
were employed in the study. Before vaccination the goats were
tested to insure that they were negative for both serum VN
antibodies, serum CpHV-1-specific IgG and vaginal CpHV-1-
specific IgG [18].
Virus, inactivated vaccine and virus challenge
The CpHV-1 Ba.1 strain [19] was used throughout the study to
prepare: i) the inactivated vaccine; ii) the antigen for the ELISA
and iii) the inoculum for the vaginal challenge. Briefly, the virus
stock was obtained by infecting Madin Darby Bovine Kidney cells
(MDBK; ATCC LGC Standards, Milan, Italy) grown in DMEM
(Lonza, Walkersvillee, USA). The viral titer was 10
6.5 50% tissue
culture infectious doses (TCID50/50 ml). The viral suspension was
tested and found to be free from bacterial and fungal
contamination. For the vaccine preparation, the virus was
inactivated with beta-propiolactone as described by Tempesta et
al. [11]. The total amount of proteins in the inactivated CpHV-1
suspension was 180610 mg/ml. The vaginal challenge was
performed by pipetting four milliliters of virulent CpHV-1
suspension (10
5 TCID50/50 ml) into the vaginal lumen of naı ¨ve
animals or vaccinated animals.
Vaccination
The adjuvant employed in the study was the oil-in-water
emulsion MF59
TM (Novartis Vaccines and Diagnostics, Siena,
Italy). The twenty-eight goats received either 2 ml of inactivated
CpHV-1 (10
6.5 TCID50/50 ml) plus 2 ml of sterile saline solution
or received 2 ml of inactivated CpHV-1 emulsified with 2 ml of
MF59
TM or were left unvaccinated (these animals served as naı ¨ve
controls in challenge studies). Goats were employed to perform
four independent experiments conducted as follows: experiment
n.1, n=4 goats (one goat received inactivated CpHV-1 only; two
goats received inactivated CpHV-1 plus MF59
TM; one goat
remained unvaccinated); experiment n.2, n=6 goats (one goat
received inactivated CpHV-1 only; four goats received inactivated
CpHV-1 plus MF59
TM; one goat remained unvaccinated);
experiment n.3, n=9 goats (three goats received inactivated
CpHV-1 only; three goats received inactivated CpHV-1 plus
MF59
TM; three goats remained unvaccinated); experiment n.4,
n=9 goats (three goats received inactivated CpHV-1 only; three
goats received inactivated CpHV-1 plus MF59
TM; three goats
remained unvaccinated). After preparation, vaccines were imme-
diately injected subcutaneously in the neck. All goats were
vaccinated with two doses of vaccine (one dose on day 0 and
one dose on day 10). On close inspection of the injection site there
was no evidence of local reaction, granulomas or abscesses in goats
vaccinated with inactivated CpHV-1 with or without the adjuvant
MF59
TM. No systemic adverse reactions were observed in any
goat included in the study.
Collection of serum samples, vaginal washes and
peripheral blood mononuclear cells
Blood samples were aseptically obtained from the jugular vein
before each immunization (days 0 and 10) and 10 days after the
second immunization (day 20). Heparinized tubes were employed
to collect whole blood for cellular analyses. Serum was obtained
after centrifugation of non-heparinized glass tubes at 2,000 rpm
for 10 min (Beckman microfuge, Fullerton, USA). Vaginal samples
were collected by flushing the vaginal lumen with a sterile pipette
containing 2 ml of sterile PBS; the samples were then centrifuged
at 2,000 rpm for 10 min and supernatants were collected. Sera
and vaginal washes were stored at 280uC until tested.
Virus neutralization assay
Virus neutralization (VN) assays were performed as described
elsewhere [11,18]. Briefly, sera were heat-inactivated at 56uC for
30 min and serial 2-fold dilutions starting from 1:2 (of each
individual sample) were mixed with 100 TCID50 of CpHV-1 Ba.1
strain in 96-well microtiter plates (Corning Inc., NY, USA). The
plates were kept at room temperature for 45 min, and then 20,000
MDBK cells were added to each well. After incubation for 3 days
at 37uC with 5% of CO2, the endpoint titers were determined
using the Spearman-Karber method and expressed as the highest
serum dilution able to neutralize the cytopathic effect.
ELISA for measurement of IgG, IgG subclasses and IgA
The ELISA tests employed to determine the titers of CpHV-1-
specific IgG or IgA in serum and vaginal washes and the titers of
CpHV-1-specific serum IgG1/IgG2 subclasses are described
elsewhere [18,20]. Briefly, 96-well polystyrene plates (Nunc,
Roskilde, Denmark) were coated with CpHV-1 diluted in
carbonate buffer and incubated overnight at 4uC on a shaker.
After blocking and washing steps, serial 2-fold dilutions of
individual sera or vaginal washes were added to duplicate wells.
After incubation overnight at 4uC, plates were washed and HRP-
conjugated rabbit anti-goat IgG (Bethyl, Montgomery, USA) or
HRP-conjugated rabbit anti-goat IgA (Bethyl) or HRP-conjugated
sheep anti-bovine IgG1 (Bethyl) or HRP-conjugated sheep anti-
bovine IgG2 (Bethyl) were added to the wells and incubated
overnight at 4uC. After final washings and addition of ABTS, the
colorimetric reaction was measured at 405 nm with an ELISA
plate reader (Biorad, Hercules, USA). The O.D. values were
recorded and individual readings were reported by subtracting the
O.D. values of negative control sera to the individual O.D. values.
The antibody titers were determined as the reciprocal of the
highest sample dilution exhibiting an O.D. value of 0.2 units above
the O.D. of negative control sera.
Vaccine-Induced Protective Immunity to CpHV-1
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Peripheral blood mononuclear cells (PBMC) were isolated from
heparinized blood samples using the standard density-gradient
separation procedure (Lympholyte, CEDARLANE laboratories
Ltd., Burlington, NC, USA) and washed twice with sterile HBSS.
PBMC at 2610
6 viable cells/ml were incubated for 5 days at 37uC
with 5% CO2 in complete medium (RPMI 1640 supplemented
with 100 U/ml penicillin, 100 mg/ml streptomycin, 2 mM L-
glutamine, 10% heat-inactivated FBS) for determination of
cytokine secretion. PBMC cultures were stimulated with inacti-
vated CpHV-1 (10 mg/ml) since previous studies [21] showed that
optimal cytokine secretion was induced with that amount of
antigen; MDBK cell lysates without virus did not stimulate
cytokine secretion thus excluding any cell-specific cytokine
response. Cultures left unstimulated served as negative controls.
In each experiment, parallel cultures were set up with PBMC
isolated from goats: i) vaccinated with inactivated CpHV-1 only; ii)
vaccinated with inactivated CpHV-1 plus MF59
TM; iii) naı ¨ve. The
levels of soluble IL-4 in culture supernatants were measured by
using a commercially available ELISA kit (Thermo Scientific)
shown to be able to detect caprine IL-4 [21] and the test was
performed according to the manufacturer’s instructions. The levels
of soluble IFN-gamma in culture supernatants were determined by
using a commercially available ELISA kit (Bovigam, Prionics,
Victoria, Australia) with a modification since quantification was
achieved by using bovine recombinant IFN-gamma (Thermo
Scientific) as a standard. The sensitivity of the IL-4 and IFN-
gamma kits was 5 pg/ml. For the measurement of IFN-gamma
spot-forming cells (IFN-gamma SFC) a commercially available
ELISPOT kit specific for bovine IFN-gamma and cross-reactive
with caprine IFN-gamma [21] was employed and the test was
performed according to the manufacturer’s instructions. In
particular, PBMC suspensions were directly cultured onto
nitrocellulose-well plates included in the kit (Thermo Scientific,
Rockford, IL, USA) and IFN-gamma SFC were counted with the
aid of a dissecting microscope (Leica MS5, Leica Microsystems
Srl, Milan, Italy).
Titration of viral shedding and measurement of clinical
scores after vaginal challenge
All animals (vaccinated and unvaccinated) were subjected to
vaginal challenge with 4 ml of virulent CpHV-1 (10
5 TCID50/
50 ml) and were kept under observation for 14 days. The challenge
was performed two weeks following the second immunization (i.e.,
day 25 post first immunization) in vaccinated animals. Following
the challenge, viral shedding was measured according to Tempesta
et al. [12]. Briefly, vaginal swabs were collected daily and placed in
1.5 ml of DMEM then were centrifuged at 10,000 rpm for 5 min.
The supernatant was collected (0.9 ml), treated with 0.1 ml of an
antibiotic solution (5,000 IU/ml penicillin, 2,500 mg/ml strepto-
mycin and 10 mg/ml amphotericin B) and incubated for 30 min at
room temperature. Each sample was serially diluted (10-fold), and
inoculated (in quadruplicate) onto MDBK cells placed in 96-well
microtiter plates (Corning). Plates were incubated for 3 days at
37uC with 5% CO2 and the virus titer was measured as previously
described [12]. After the challenge, goats were also examined daily
to evaluate the severity of the CpHV-1 infection. The body
temperature was measured, and general and local clinical signs
were recorded (i.e., hyperemia, edema, lesions, pain). A cumula-
tive clinical score was determined in each animal by grading the
clinical signs as follows: 0, absent; 1, mild; 2, moderate; and 3,
severe. Temperature increments above normal (the normal body
temperature ranged from 38.2 to 38.6uC) were graded as follows:
.0.5–1uC=1;.1.1–1.5uC=2;.1.5uC=3.
Real-time PCR
A real-time PCR assay was employed to detect and quantitate
CpHV-1 genomic DNA in vaginal swabs (collected daily for 14
days after the challenge) and sacral ganglia (excised one month
after challenge). The assay was conducted as previously reported
[22]. Briefly, samples (i.e., 200 ml of the swab or 25 mg of each
ganglion) were processed to extract the DNA (QIAGEN S.p.A.
Italy). Primers, probes, and CpHV-1 DNA standards employed in
the real-time PCR assay were designed to target a conserved
region of the gC gene of CpHV-1 Ba.1 strain [22]. An internal
control (canine parvovirus type 2 DNA) was included in each assay
to exclude any loss of DNA during the extraction and
amplification steps. The analytical performance of the real-time
PCR assay employed in this study was comparable to that
reported previously [22,23] while the detection limit of the assay
was 5610
1 standard DNA copies/10 ml of template.
Statistical analysis
Data are expressed as arithmetic mean 6 SD of the: i) log2
transformed VN titers; ii) log2 transformed serum IgG/vaginal
IgG/serum IgG subclass titers; iii) soluble IFN-gamma levels; iv)
numbers of IFN-gamma SFC; v) log10 transformed viral shedding
titers; vi) numbers of CpHV-1 genomes in vaginal swabs; vi)
clinical scores.
Data on latency in sacral ganglia are expressed as arithmetic
mean 6 SEM of the log10 transformed number of CpHV-1
genomes.
Data recorded from day 0 to day 14 post challenge (i.e, vaginal
CpHV-1 shedding titers, number of CpHV-1 genomes in vaginal
swabs and clinical scores) were used to calculate the Area Under
Curve (AUC).
Data were analyzed by the one-way ANOVA test followed by
the Tukey’s post-hoc test for multiple comparisons.
The difference between log2 serum anti-CpHV-1 IgG1 and
IgG2 titers (within the same vaccine group) was analyzed by the
Students’ t-test.
The software R (version 2.8.1) was employed to perform all tests.
A p value less than 0.05 was considered significant.
Results
CpHV-1-specific serum IgG and VN antibodies induced
after vaccination with inactivated CpHV-1 plus MF59
TM
To study the immunogenicity of the inactivated CpHV-1 plus
MF59
TM vaccine, VN antibodies and IgG specific to CpHV-1
were measured in serum. Both parameters were measured in sera
drawn before vaccination (day 0), ten days after the first dose of
vaccine (day 10) and ten days after the second dose of vaccine (day
20). In order to evaluate the adjuvant activity of MF59
TM, goats
vaccinated with inactivated CpHV-1 only were used as controls
while naı ¨ve goats served as background controls. It should be
noted that day 0 samples from all vaccinated and naı ¨ve goats had
undetectable levels of: i) VN serum antibodies; ii) CpHV-1-specific
serum IgG and iii) CpHV-1-specific vaginal IgG (as these were
inclusion criteria for the current study).
As shown in figure 1A, after the first dose of the vaccines (i.e.,
day 10 sera), goats exhibited a variable VN antibody response to
CpHV-1. In particular, in goats vaccinated with inactivated
CpHV-1 only, the average VN titers were slightly above those of
naı ¨ve goats (,log2 1 in naı ¨ve goats; log2 1.360.6 in goats
vaccinated with inactivated CpHV-1 only) while goats vaccinated
with inactivated CpHV-1 plus MF59
TM showed average VN titers
(log2 3.462) which were 4- to 8-fold higher than those of naı ¨ve
Vaccine-Induced Protective Immunity to CpHV-1
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inactivated CpHV-1 only.
After the administration of the second dose of the vaccine i.e.,
on day 20 post immunization (Fig. 1A), VN titers increased in
goats immunized with CpHV-1-only but reached average titers
(log2 261) that were only 2-fold higher than those of naı ¨ve
animals. In contrast, goats vaccinated with inactivated CpHV-1
plus MF59
TM developed significantly elevated VN titers (log2
7.460.5) on day 20 which were approximately 128-fold higher
than those of naı ¨ve goats and 64-fold higher than those of goats
vaccinated with inactivated CpHV-1 only.
Figure 1B shows that after the first dose of the vaccines, i.e., on
day 10 post immunization, the titers of CpHV-1-specific serum
IgG in goats vaccinated with inactivated CpHV-1 only (log2 662),
were 4-fold above those of naı ¨ve goats (,log2 5) while goats
vaccinated with inactivated CpHV-1 plus MF59
TM developed IgG
titers (log2 1261.4) that were 256-fold above those of naı ¨ve goats.
The second dose of the vaccines boosted the serum IgG responses
in all goats although goats vaccinated with inactivated CpHV-1
only exhibited average IgG titers (log2 9.861) on day 20 post
immunization that were 64-fold higher than those of naı ¨ve goats
while goats vaccinated with inactivated CpHV-1 plus MF59
TM
developed significant titers of serum IgG specific to CpHV-1 (log2
1660.5) which were approximately 64-fold higher than titers
measured in goats vaccinated with inactivated CpHV-1 only and
were at least 4096-fold higher than those of naı ¨ve goats.
Titers of IgG1 and IgG2 specific to CpHV-1 were measured in
sera from all vaccinated goats after the second immunization i.e.,
at day 20, to study the relative contribution of IgG subclasses to
the observed IgG response [20,24]. Goats vaccinated with
inactivated CpHV-1 only, produced low titers of both IgG1 and
IgG2 subclasses (log2 761.1 and log2 7.261.1, respectively) (Fig. 2)
which were an average 8-fold higher than background levels in
naı ¨ve goats (,log2 5). In contrast, goats vaccinated with
inactivated CpHV-1 plus MF59
TM exhibited titers of serum
IgG1 (log2 12.860.4) that were an average 256-fold higher than
those of naı ¨ve goats and titers of serum IgG2 (log2 14.360.5) that
were an average 512-fold higher than those of naı ¨ve goats. In
addition, in goats vaccinated with CpHV-1 plus MF59
TM titers of
serum IgG2 were significantly higher than those of IgG1 (Fig. 2).
Figure 1. Serum and vaginal antibody responses in goats
subcutaneously vaccinated with inactivated CpHV-1 plus
MF59
TM. Vaccines were given on day 0 and day 10. Sera and vaginal
washes were collected on day 10 (white histograms) and day 20 (black
or dashed histograms) to determine serum VN titers (A) or ELISA serum
IgG titers (B) or ELISA vaginal IgG titers (C). Data are expressed as
arithmetic mean 6 SD. Data reported are cumulative from 4
independent experiments performed as described in Materials and
Methods with a total of 8 goats in the naı ¨ve group, a total of 8 goats in
the inactivated CpHV-1 only vaccinated group and a total of 12 goats in
the inactivated CpHV-1 plus MF59
TM vaccinated group. A double
asterisk (**) denotes probability, p, ,0.001 that the VN titers (A) or the
serum IgG titers (B) or the vaginal IgG titers (C) in goats vaccinated with
inactivated CpHV-1 plus MF59
TM were equivalent to those of naı ¨ve
goats on day 20 post immunization. The same probability, p, ,0.001
was observed when VN titers (A), serum IgG titers (B) and vaginal IgG
titers (C) in goats vaccinated with inactivated CpHV-1 plus MF59
TM were
compared to those of goats vaccinated with inactivated CpHV-1 only on
day 20 post immunization. Statistical differences were calculated by the
one-way ANOVA test followed by the Tukey’s post-hoc test.
doi:10.1371/journal.pone.0034913.g001
Figure 2. Serum IgG subclass responses in goats subcutane-
ously vaccinated with inactivated CpHV-1 plus MF59
TM.
Vaccines were given on day 0 and day 10. Sera were collected on day
20 to determine CpHV-1-specific IgG1 titers (white histograms) and
CpHV-1-specific IgG2 titers (black histograms) by ELISA. Data are
expressed as arithmetic mean 6 SD. Data reported are cumulative from
4 independent experiments performed as described in Materials and
Methods with a total of 8 goats in the naı ¨ve group, a total of 8 goats in
the inactivated CpHV-1 only vaccinated group and a total of 12 goats in
the inactivated CpHV-1 plus MF59
TM vaccinated group. A single asterisk
(*) denotes probability, p, ,0.05 that the serum IgG1 titers are
equivalent to the serum IgG2 titers in goats vaccinated with inactivated
CpHV-1 plus MF59
TM. The Students’ t-test was employed to study
statistical differences.
doi:10.1371/journal.pone.0034913.g002
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were also studied by ELISA and they were undetectable at all time
points tested (data not shown).
Subcutaneous vaccination with inactivated CpHV-1 plus
MF59
TM results in CpHV-1-specific vaginal IgG
The systemic immune system may contribute to local protection
in the genital mucosa with antibodies transudating from serum
into vaginal secretions [25–28]. Since the inactivated CpHV-1
plus MF59
TM vaccine induced high serum titers of antigen-specific
IgG and high VN titers, the same parameters were measured in
vaginal washes collected from vaccinated goats. After administra-
tion of the first vaccine dose (i.e., samples collected on day 10),
none of the goats vaccinated with CpHV-1 only exhibited
detectable CpHV-1-specific vaginal IgG (,log2 1; Fig. 1C) while
animals vaccinated with inactivated CpHV-1 plus MF59
TM
exhibited low titers of vaginal IgG (log2 160.5) which were an
average 2-fold higher than those of naı ¨ve goats (,log2 1; Fig. 1C).
Administration of the second vaccine dose (i.e., samples collected
on day 20) resulted in significantly elevated titers of CpHV-1-
specific vaginal IgG (log2 461) in goats vaccinated with inactivated
CpHV-1 plus MF59
TM and these antibody titers were an average
16-fold higher than those of naı ¨ve goats (Fig. 1C). On day 20 post
immunization, CpHV-1-specific vaginal IgG remained undetect-
able in goats vaccinated with inactivated CpHV-1 only.
It should be noted that the levels of vaginal IgG in the three
groups of goats were different despite the presence of similar levels
of albumin in vaginal samples (data not shown) suggesting that
vaginal IgG in goats vaccinated with inactivated CpHV-1 plus
MF59
TM reflected the higher levels of serum IgG in this group of
animals rather than resulting from an augmented mucosal
permeability.
The level of VN activity in vaginal washes from all vaccinated
goats was undetectable even after the second immunization (i.e.,
day 20) and this was likely due to the dilution of vaginal antibodies
during the collection of the sample [29]. No CpHV-1-specific
vaginal IgA were detected in any animal in response to the
vaccines at any time (data not shown).
Production of IFN-gamma by antigen-specific PBMC from
goats vaccinated with inactivated CpHV-1 plus MF59
TM
The profile of IFN-gamma and IL-4 secretion by PBMC
isolated from vaccinated goats (following the second immunization
i.e., on day 20) was studied in culture supernatants after CpHV-1
stimulation. As shown in Fig. 3A, PBMC isolated from goats
vaccinated with inactivated CpHV-1 only and from naı ¨ve goats
did not produce detectable levels of IFN-gamma upon antigen-
stimulation in vitro. Goats vaccinated with inactivated CpHV-1
plus MF59
TM exhibited significant levels of soluble IFN-gamma
(3436101 pg/ml) in response to in vitro antigen stimulation and
these levels were approximately 150-fold higher than those of
either naı ¨ve goats or goats vaccinated with inactivated CpHV-1
only (,5 pg/ml). In the same cultures, IL-4 was always
undetectable in response to CpHV-1 stimulation (data not shown).
Mitogen-stimulated PBMC cultures from all vaccinated goats and
from naı ¨ve goats, secreted similar amounts of both IFN-gamma
and IL-4 (data not shown) indicating that the ability to produce
IFN-gamma or IL-4 was intact and comparable in all goats.
The frequencies of CpHV-1-specific IFN-gamma producing
cells were measured by ELISPOT (Fig. 3B) and PBMC from goats
vaccinated with inactivated CpHV-1 plus MF59
TM developed
significantly more IFN-gamma producing cells (105618/10
6
PBMC) relative either to naı ¨ve goats or to goats vaccinated with
inactivated CpHV-1 only (,1 IFN-gamma SFC/10
6 PBMC).
An inactivated CpHV-1 plus MF59
TM vaccine reduces viral
replication and protects against vaginal diseases in goats
vaginally challenged with virulent CpHV-1
To determine the efficacy of the inactivated CpHV-1 plus
MF59
TM vaccine, all vaccinated goats were vaginally infected with
4 ml of virulent CpHV-1 suspension (10
5 TCID50/50 ml) two
weeks after the second immunization and were monitored daily,
for 14 days, in order to record the severity of disease and the
vaginal virus shedding. The kinetics of these parameters was
determined and the area under curve (AUC) was calculated in
each goat for statistical comparisons. Naı ¨ve goats were vaginally
infected and used as unvaccinated controls. Figure 4A shows that
from day 1 to day 14 post challenge, goats immunized with
inactivated CpHV-1 only and naı ¨ve goats shed titers of challenge
virus (measured by the standard cell-culture method) that were not
significantly different. In particular, from day 1 to day 6 post
challenge, the above groups of goats showed a similar trend of
active local virus replication as they shed increasing titers of
challenge virus that reached maximal levels by day 6. (log10
2.661.4 on day 1 and log10 5.861.1 on day 6 in naı ¨ve goats; log10
0.560.3 on day 1 and log10 4.561.5 on day 6 in goats vaccinated
with inactivated CpHV-1 only). In the same groups of goats, the
shedding of challenge virus started to decrease from day 7 post
challenge to reach undetectable levels on days 13–14. On the
other hand, at all time points post challenge, vaginal CpHV-1
shedding was not detected by the standard cell-culture test in any
goat vaccinated with inactivated CpHV-1 plus MF59
TM (Fig. 4A).
The shedding of challenge virus in goats vaccinated with
inactivated CpHV-1 plus MF59
TM was statistically different from
that of naı ¨ve goats and from that of goats vaccinated with
inactivated CpHV-1 only.
A parallel real-time PCR assay was performed with DNA
extracted from vaginal swabs collected daily from all challenged
goats in order to detect and quantitate the number of CpHV-1
genomes. Figure 4B shows that, from day 1 to day 14 post
challenge, the number of CpHV-1 genomes detected in vaginal
swabs from goats immunized with CpHV-1 only, did not differ
significantly from that of naı ¨ve goats. In particular, from day 1 to
day 6 post challenge both the goats vaccinated with inactivated
CpHV-1 only and the naı ¨ve goats exhibited a trend of active local
virus replication with numbers of CpHV-1 genomes increasing
from day 1 to day 6 post challenge. CpHV-1 genomes peaked at
2610
763.7610
7 on day 3 post challenge for naı ¨ve goats while the
number of CpHV-1 genomes peaked at 1.4610
761.3610
7 on day
6 post challenge for goats vaccinated with inactivated CpHV-1
only. In these same groups of goats, the number of CpHV-1
genomes progressively decreased from day 7 to day 14 post
challenge and reached levels on day 14 that were approximately
300-fold lower than those measured on day 1 post challenge in
naı ¨ve goats and approximately 20-fold lower than those measured
on day 1 post challenge in goats vaccinated with inactivated
CpHV-1 only. It was interesting to note that, in vaginal samples
obtained from goats vaccinated with inactivated CpHV-1 only and
from naı ¨ve goats, the CpHV-1 DNA remained detectable on day
13 and on day 14 post challenge (Fig. 4B) when the titration of
infectious virus by the cell-culture test gave negative results in the
majority of goats (Fig. 4A).
A different vaginal CpHV-1 genome profile was observed in
goats vaccinated with inactivated with CpHV-1 plus MF59
TM
(Fig. 4B). In fact, a decreasing number of CpHV-1 genomes was
detected from day 1 to day 11 post challenge and from day 12 post
Vaccine-Induced Protective Immunity to CpHV-1
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swabs from this group of vaccinated goats (Fig. 4B). In addition,
the number of vaginal CpHV-1 genomes measured from day 1 to
day 14 post challenge was significantly different from that of naı ¨ve
goats as well as from that of goats immunized with inactivated
CpHV-1 only. It is remarkable that, in goats vaccinated with
inactivated CpHV-1 plus MF59
TM, the infectious challenge virus
was undetectable by the standard cell-culture test from day 1 to
day 14 post challenge (Fig. 4A) and this was probably due to
neutralization of the virus (whose genome was detected) by the
antigen-specific vaginal antibodies (Fig. 1C). In addition, the
number of CpHV-1 genomes detected on day 1 post challenge in
vaginal swabs from goats vaccinated with inactivated CpHV-1
plus MF59
TM (2.7610
462.0610
4) was approximately 20-fold
lower than that measured in swabs from naive goats
(5.7610
564.8610
5) and approximately 4-fold lower than that
measured in goats vaccinated with inactivated CpHV-1 only
(1.1610
569.7610
4) (Fig. 4B). Since all the animals were
experimentally infected with an identical amount of challenge
virus, the differences in the level of vaginal CpHV-1 genomes on
day 1 post challenge could be due to the immune responses
induced by the adjuvanted vaccine that could interfere with virus
replication.
Clinical scores were also recorded after the vaginal challenge to
monitor the clinical efficacy of the vaccine formulations (Fig. 4C).
Goats vaccinated with inactivated CpHV-1 without adjuvant
showed a significantly less severe clinical disease (characterized by
milder lesions and faster healing) when compared to naı ¨ve animals
that showed all the classical signs and kinetics of the herpetic
disease [10–12,23]. Challenge with virulent CpHV-1 did not
produce any overt disease (that was evident upon visual inspection
of the vaginas) in any goat vaccinated with inactivated CpHV-1
plus MF59
TM (Fig. 4C). However, since histological analysis was
not performed on CpHV-1-infected vaginal mucosae it is was not
Figure 3. IFN-gamma production by PBMC isolated from goats subcutaneously vaccinated with inactivated CpHV-1 and MF59
TM.
Vaccines were given on day 0 and day 10. Blood was drawn on day 20 and PBMC were isolated and stimulated in vitro as described in Materials and
Methods. Soluble IFN-gamma in culture supernatants was measured by ELISA (A) while frequencies of IFN-gamma Spot Forming Cells (SFC) were
measured by ELISPOT (B). Data (arithmetic mean 6 SD) are cumulative from 4 independent experiments performed as described in Materials and
Methods with a total of 8 goats in the naı ¨ve group, a total of 8 goats in the inactivated CpHV-1 only vaccinated group and a total of 12 goats in the
inactivated CpHV-1 plus MF59
TM vaccinated group. A double asterisk (**) denotes probability, p, ,0.001 that the soluble IFN-gamma levels (A) or the
IFN-gamma SFC (B) in goats vaccinated with inactivated CpHV-1 plus MF59
TM were equivalent to those of naı ¨ve goats. The same probability, p,
,0.001 was observed when soluble IFN-gamma levels (A) or IFN-gamma SFC (B) in goats vaccinated with inactivated CpHV-1 plus MF59
TM were
compared to those of goats vaccinated with inactivated CpHV-1 only. Statistical differences were calculated by the one-way ANOVA test followed by
the Tukey’s post-hoc test.
doi:10.1371/journal.pone.0034913.g003
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PLoS ONE | www.plosone.org 6 April 2012 | Volume 7 | Issue 4 | e34913Figure 4. Vaginal viral shedding and clinical scores in goats vaccinated with inactivated CpHV-1 and challenged vaginally with
virulent CpHV-1. Vaccines were given on day 0 and day 10. All goats were challenged vaginally two weeks following the second vaccination as
described in Materials and Methods with 4 ml of virulent CpHV-1 suspension (10
5 TCID50/50 ml). Naı ¨ve goats were included as unvaccinated controls.
Goats were monitored daily for 14 days post-challenge and vaginal swabs were collected daily and employed to quantitate the viral shedding.
Titration of the infectious virus in vaginal swabs was achieved by measuring the cytopathic effect of serial dilutions of the sample in MDBK cultures
(A) while the number of CpHV-1 genomes in vaginal swabs was measured by real-time PCR (B). Clinical scores were also recorded daily following the
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pathological changes that were not visible upon gross examination
of goats.
Frequencies of CpHV-1-specific IFN-gamma producing
cells in goats vaginally challenged with virulent CpHV-1
To determine the effect of the experimental infection on IFN-
gamma production, PBMC were isolated from all challenged goats
three weeks post-challenge and frequencies of IFN-gamma
secreting cells were measured after CpHV-1 in vitro stimulation.
As depicted in Figure 5, IFN-gamma producing cells were
detected at similar levels in goats vaccinated with inactivated
CpHV-1 only (1765 IFN-gamma SFC/10
6 PBMC) and in naı ¨ve
goats (1868 IFN-gamma SFC/10
6 PBMC) while the frequencies
of IFN-gamma producing cells in goats vaccinated with inactivated
CpHV-1 plus MF59
TM (92618 IFN-gamma SFC/10
6 PBMC)
were significantly higher (an average 5-fold higher) than those
observed in naı ¨ve goats or in goats vaccinated with inactivated
CpHV-1 only. In addition, the frequency of IFN-gamma
producing cells remained stable before and after vaginal challenge
in goats vaccinated with inactivated CpHV-1 plus MF59
TM
(Fig. 3B and Fig. 5).
Subcutaneous vaccination with inactivated CpHV-1 plus
MF59
TM interferes with the establishment of latency after
vaginal challenge
To determine whether the inactivated CpHV-1 plus MF59
TM
vaccine influenced the establishment of latency, sacral ganglia
were isolated from all challenged goats and subjected to a real-time
PCR assay to detect and quantitate the latent CpHV-1 load. As
reported previously [23], CpHV-1 DNA was variably detected in
all five pairs of sacral ganglia isolated from naı ¨ve goats and a
similar trend was observed in goats vaccinated with inactivated
CpHV-1 only (Fig. 6A and 6B) thereby confirming that the
amount and distribution of latent CpHV-1 in sacral ganglia do not
appear to be related to the severity of the clinical signs of disease
following challenge [23].
In naı ¨ve goats, the latent CpHV-1 genomes were most
abundantly found in the second, third and fourth pair of sacral
ganglia and they were approximately 1,500 times, 1,000,000
times, and 3,500 times above the limit of detection of the real-time
PCR assay for the second, the third and the fourth ganglia,
respectively (log10 1.860.8 for the first pair; log10 3.061.8 for the
second pair; log10 5.461.5 for the third pair; log10 4.161.7 for the
fourth pair; log10 2.161.1 for the fifth pair). In addition, in naı ¨ve
goats, CpHV-1 genomes were detected in 3 out of 12 first sacral
ganglia (the average number of CpHV-1 genomes in these 3
ganglia was 40 times above the limit of detection of the real-time
PCR assay) and in 4 out of 12 fifth sacral ganglia (the average
number of CpHV-1 genomes in these 4 ganglia was 100 times
above the limit of detection of the real-time PCR assay).
It was interesting to note that, in goats vaccinated with
inactivated CpHV-1 plus MF59
TM, the CpHV-1 genome was
undetectable in 58 out of 60 sacral ganglia examined and in
particular it was undetectable in: i) 11 out 12 first sacral ganglia
(with a number of CpHV-1 genomes in the latently infected
ganglion being 35 times above the limit of detection of the real-
time PCR assay); ii) 12 out of 12 second sacral ganglia; iii) 12 out
of 12 third sacral ganglia; iv) 11 out of 12 fourth sacral ganglia
(with a number of CpHV-1 genomes in the latently infected
ganglion being less than 2 times above the limit of detection of the
real-time PCR assay); v) 12 out of 12 fifth sacral ganglia. In goats
vaccinated with inactivated CpHV-1 plus MF59
TM, the number of
latent CpHV-1 genomes in the second, third, fourth and fifth pair
of sacral ganglia was significantly different from that of naı ¨ve
goats. Indeed, in four out of six goats vaccinated with CpHV-1
plus MF59
TM, the CpHV-1 genome was undetectable in all five
pairs of sacral ganglia while the remaining two goats had
detectable latent CpHV-1 DNA in one single ganglion (one goat
in the first left ganglion and one goat in the fourth right ganglion).
challenge (C). Data (arithmetic mean 6 SD) are cumulative from 4 independent experiments performed as described in Materials and Methods with a
total of 8 goats in the naı ¨ve group, a total of 8 goats in the inactivated CpHV-1 only vaccinated group and a total of 12 goats in the inactivated CpHV-
1 plus MF59
TM vaccinated group. In (A), (B) and (C) the double asterisk (**) denotes probability, p, ,0.001 that the CpHV-1 shedding titers (A) or the
number of CpHV-1 genomes (B) or the clinical scores (C) in goats vaccinated with inactivated CpHV-1 plus MF59
TM were equivalent to those of naı ¨ve
goats. The same probability, p, ,0.001 was observed when the CpHV-1 shedding titers (A) or the number of CpHV-1 genomes (B) or the clinical
scores (C) in goats vaccinated with inactivated CpHV-1 plus MF59
TM were compared to those of goats vaccinated with inactivated CpHV-1 only. In (C)
the single asterisk denotes probability, p, ,0.05 that the clinical scores in goats vaccinated with inactivated CpHV-1 only were equivalent to those of
naı ¨ve goats. Data depicted in (A), (B) and (C), were used to calculate the AUC in order to perform statistical analyses. Statistical differences were
calculated by the one-way ANOVA test followed by the Tukey’s post-hoc test.
doi:10.1371/journal.pone.0034913.g004
Figure 5. IFN-gamma SFC in PBMC isolated from goats
subcutaneously vaccinated with inactivated CpHV-1 and
challenged vaginally with virulent CpHV-1. Vaccines were given
on day 0 and day 10. All goats were challenged vaginally two weeks
following the second vaccination with 4 ml of virulent CpHV-1
suspension (10
5 TCID50/50 ml) as described in Materials and Methods.
Blood was drawn three weeks post-challenge and PBMC were isolated
and stimulated in vitro as described in Materials and Methods.
Frequencies of IFN-gamma Spot Forming Cells (SFC) were measured
by ELISPOT. Data (arithmetic mean 6 SD) are cumulative from 4
independent experiments performed as described in Materials and
Methods with a total of 8 goats in the naı ¨ve group, a total of 8 goats in
the inactivated CpHV-1 only vaccinated group and a total of 12 goats in
the inactivated CpHV-1 plus MF59
TM vaccinated group. A single asterisk
(*) denotes probability, p, ,0.05 that the IFN-gamma SFC in goats
vaccinated with inactivated CpHV-1 plus MF59
TM were equivalent to
those of naı ¨ve goats. The same probability, p, ,0.05 was observed
when IFN-gamma SFC in goats vaccinated with inactivated CpHV-1 plus
MF59
TM were compared to those of goats vaccinated with inactivated
CpHV-1 only. Statistical differences were calculated by the one-way
ANOVA test followed by the Tukey’s post-hoc test.
doi:10.1371/journal.pone.0034913.g005
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In this study subcutaneous administration of a whole inactivated
CpHV-1 vaccine plus MF59
TM was able to confer effective
protection against vaginal CpHV-1 challenge in goats. The
vaccine-induced immune responses were protective as they
reduced the replication of challenge virus in the genital mucosa
to undetectable levels and significantly reduced the establishment
of latency in sacral ganglia after challenge. Since the latent viral
load is the most relevant factor that predicts reactivation rates of
animals latently infected with HSV [30,31], the present results
suggest that vaccination with inactivated CpHV-1 plus MF59
TM
could at least influence the rate of recurrent infections thereby
reducing the transmission of the infection to other animals in the
same flock. To our knowledge this is the first study showing that a
similar level of protection against an alphaherpesvirus could be
achieved in a natural host by vaccination.
MF59
TM is a detergent-stabilized oil-in-water emulsion consist-
ing of small drops of oil (squalene) surrounded by a monolayer of
non-ionic detergents. [14]. MF59
TM is able to increase the
immunogenicity of several types of antigens, promotes both
antibody and cell-mediated immune responses and has an
excellent safety record [14–17,32]; it is indeed licensed for human
use in the European Union and it is a component of seasonal and
pandemic injectable human flu-vaccines [33]. The adjuvant
MF59
TM has been administered, mostly by the intramuscular
route, to several animal species (from rodents to non-human
primates) though data in ruminants are limited to immunogenicity
not to vaccine efficacy [34]. After intramuscular delivery, muscle
cells were shown to be targets of MF59
TM [35,36], and its
adjuvant activity could be associated with the active recruitment of
antigen presenting cells to the injection site. The high efficacy of
MF59
TM observed in the present study following subcutaneous
administration with inactivated CpHV-1 could be due to the
crucial role played by epidermal and dermal dendritic cells in
priming naı ¨ve T cells [37–40]. In addition, the use of a whole virus
as immunogen, rather than single glycoproteins, could have
contributed to the observed high efficacy due to the presence of
natural TLR ligands in the vaccine. In this regard, human trials
have shown that HSV-2 subunit vaccines (containing gB and gD)
are unable to confer full protection in humans [41–43]. However,
it should be underlined that although, in the veterinary field, the
use of a classical whole inactivated virus as immunogen could be
more practical and less expensive than the use of individual
antigens, further studies are mandatory in order to identify
potential protective CpHV-1 antigens that could be tested for
immunogenicity and efficacy in vaccination protocols.
The present study suggests that IgG produced following
parenteral immunization of goats could transudate from serum
to vaginal secretions contributing to protective immunity against
vaginal CpHV-1 infection. The presence of Ag-specific IgG in the
preferential site of entry of CpHV-1 would provide a first line of
defense against infection that could be further implemented by the
physiologic increase in serum transudation which occurs during
Figure 6. Distribution and quantitation of CpHV-1 genomic
DNA in sacral ganglia from goats vaccinated with inactivated
CpHV-1 and challenged with virulent CpHV-1. Vaccines were
given on day 0 and day 10. All goats were challenged vaginally two
weeks following the second vaccination with 4 ml of virulent CpHV-1
suspension (10
5 TCID50/50 ml) as described in Materials and Methods.
The five pairs of sacral ganglia were excised one month after challenge,
the DNA was extracted from individual ganglion to detect and
quantitate the number of CpHV-1 genomes by real-time PCR. Data
(arithmetic mean 6 S E M )a r ec u m u l a t i v ef r o m2i n d e p e n d e n t
experiments i.e., experiment n.3 and experiment n.4, performed as
described in Materials and Methods with a total of 6 goats in the naı ¨ve
group, a total of 6 goats in the inactivated CpHV-1 only vaccinated
group and a total of 6 goats in the inactivated CpHV-1 plus MF59
TM
vaccinated group. White circles (right ganglia), black circles (left
ganglia). A single asterisk (*) denotes probability, p, ,0.05 that the
number of CpHV-1 genomes in the second (or in the fifth) pair of
ganglia of goats vaccinated with inactivated CpHV-1 plus MF59
TM was
equivalent to that of naı ¨ve goats. A double asterisk (**) denotes
probability, p, ,0.001 that the number of CpHV-1 genomes in the third
(or in fourth) pair of ganglia of goats vaccinated with inactivated CpHV-
1 plus MF59
TM was equivalent to that of naı ¨ve goats. Statistical
differences were calculated by the one-way ANOVA test followed by the
Tukey’s post-hoc test.
doi:10.1371/journal.pone.0034913.g006
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1-specific serum IgG and VN antibodies could contribute to
protection by intercepting the virus escaped from the mucosa.
Indeed, it is remarkable that serum antibodies specific to HSV
have been shown to: i) neutralize herpesviruses at the axon
terminus/synapses; ii) promote intra-axonal neutralization; iii)
inhibit axonal spread to epidermal cells [46,47]. Consistent with
the above findings, the inactivated CpHV-1 plus MF59
TM vaccine
was able to interfere with the replication of CpHV-1 in the genital
mucosa and to significantly reduce the load of latent CpHV-1 in
sacral ganglia. Indeed, in some animals (i.e., 4 out of 6) immunized
with inactivated CpHV-1 plus MF59
TM, the vaccine was able to
reduce the establishment of latency to undetectable levels in all five
pairs of sacral ganglia.
Several studies on immunity to HSV-1/HSV-2 vaccines
[42,43,48–51] as well as studies on immunity elicited by
inactivated whole MCMV vaccines [52–54] have shown that
antigen-specific antibody responses produced after immunization
are only able to limit the severity of the disease caused by these
herpesviruses and that T cell responses play a major role in
controlling primary infection and reactivations. Results from the
present study seem to extend this observation also to CpHV-1.
Indeed, immune serum antibodies generated following immuni-
zation seem to provide only partial protection from genital disease
(e.g, as it occurs in goats vaccinated with inactivated CpHV-1
only), while appear to leave unabated acute viral replication in the
genital mucosa thereby allowing the establishment of a latent
infection in sacral ganglia. The data reported here suggest that, in
goats vaccinated with inactivated CpHV-1 plus MF59
TM, CpHV-
1-specific vaginal IgG and IFN-gamma production are associated
with protective immunity against vaginal CpHV-1 infection
although the relative contribution of antibody (mucosal and/or
systemic) and IFN-gamma production to protection against
vaginal CpHV-1 challenge remains to be specifically addressed
in future studies.
The adjuvant MF59
TM was able to induce high levels of
antigen-specific IFN-gamma which is a key soluble mediator in
control and resolution of HSV-2 infection [55–59]. Although,
IFN-gamma is a major cytokine produced by T helper 1
lymphocytes and it induces CD8
+ CTL, future studies will be
necessary to determine the contribution of each PBMC subset
(e.g., CD4
+, CD8
+, WC1
+, NK) to IFN-gamma production in
goats vaccinated with inactivated CpHV-1 plus MF59
TM.I n
addition, the analysis should be expanded to other cytokines and
chemokines to test whether other soluble mediators contribute to
the protection observed in goats vaccinated with inactivated
CpHV-1 plus MF59
TM.
Two caveats of the current study are that: i) challenge was
perfomed only two weeks following the second immunization; ii)
only female goats were vaccinated. Future studies should employ
larger numbers of animals of both sexes and longer time intervals
should be allowed between vaccination and challenge. These
studies would determine if the protective effect elicited by the
inactivated CpHV-1 plus MF59
TM vaccine persists for longer
periods and could prove if the vaccine is also effective in males.
In conclusion, this is the first study showing that MF59
TM in
goats: i) provides effective adjuvant activity when administered
subcutaneously with an inactivated CpHV-1 vaccine; ii) induces
high levels of IFN-gamma by vaccine-specific PBMC as it has been
reported in humans [60]
In perspective, due to the excellent safety and efficacy record of
MF59
TM, the current study could help design new vaccines for
pets and horses where safety and reactogenicity are primary
concerns [61,62] and for whom effective vaccines against some
infectious diseases are needed (e.g, Feline Leukemia Virus, Feline
and Canine Coronavirus, Canine and Equine Herpesvirus).
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